Laboratoire de Biochimie Théorique
Institut de **B**iologie **P**hysico-**C**himique
13, rue Pierre et Marie Curie
75005 PARIS

S E M I N A I R E

Guillaume Blivet
REGEnLIFE RESEARCH
10 rue de Penthièvre 75008 Paris

« Photobiomodulation in Alzheimer's disease: an overview of translational research from bench to bedside »

Alzheimer’s disease is a common neurodegenerative disorder characterized by progressive synaptic and neuronal loss, leading to cognitive decline. Its pathophysiology includes cerebral lesions, oxidative stress, neuroinflammation, and brain–gut axis dysbiosis. Preclinical studies show that brain photobiomodulation (bPBM) reduces oxidative stress and inflammation, improves cerebral blood flow, and enhances neurogenesis and synaptogenesis, making it a promising therapeutic approach. Clinical studies in Alzheimer’s disease demonstrate good safety and encouraging efficacy signals, but remain exploratory and heterogeneous. Future research should focus on robust double-blind, sham-controlled randomized trials and optimized dosimetry to define the clinical role of bPBM in Alzheimer’s disease.

Jeudi 29 janvier 2026
14h00
Bibliothèque